13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274413
Total reported value
$143.3M
$143.3M
94 檔
34.3%
According to the latest 13F quarterly dataset, Sectoral Asset Management Inc managed an equity portfolio of $143.3M at the end of Q2 2025, spanning 94 distinct U.S. exchange-listed positions.
Sectoral Asset Management Inc executed strategic sector rebalancing during Q2 2025, establishing 25 new positions while fully exiting 15 holdings and trimming 25 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LENZ | Lenz Therapeutics Inc | Stock-Other | 18.91% | — | — | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.62% | +0.48% | -4.67% | |
| 3 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 3.45% | +0.49% | +29.86% | |
| 4 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 3.42% | -0.47% | +3.21% | |
| 5 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 2.10% | +0.45% | — | |
| 6 | AMGN | Amgen Inc | Stock-Healthcare | 2.08% | -0.58% | +8.52% | |
| 7 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.04% | -0.98% | +46.98% | |
| 8 | JNJ | Johnson & Johnson | Stock-Healthcare | 1.95% | -0.46% | -11.47% | |
| 9 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.88% | -0.38% | — | |
| 10 | ABBV | Abbvie Inc | Stock-Healthcare | 1.81% | -0.06% | — | |
| 11 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.55% | -0.10% | +1057.42% | |
| 12 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.50% | -0.73% | -12.80% | |
| 13 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.49% | -0.44% | +31.65% | |
| 14 | MBX | Mbx Biosciences Inc | Stock-Other | 1.45% | — | — | |
| 15 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.44% | -1.60% | -38.51% | |
| 16 | PVLA | Palvella Therapeutics Inc | Stock-Other | 1.42% | — | — | |
| 17 | REPL | Replimune Group Inc | Stock-Other | 1.42% | — | — | |
| 18 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.38% | +1.53% | +857.46% | |
| 19 | DHR | Danaher CORP | Stock-Healthcare | 1.38% | -0.23% | — | |
| 20 | ABT | Abbott Laboratories | Stock-Healthcare | 1.36% | -1.04% | -18.72% | |
| 21 | SLDB | Solid Biosciences Inc | Stock-Other | 1.36% | — | — | |
| 22 | RAPP | Rapport Therapeutics Inc | Stock-Other | 1.35% | -0.69% | EXIT | |
| 23 | ZBIO | Zenas Biopharma Inc | Stock-Other | 1.35% | — | — | |
| 24 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 1.32% | — | — | |
| 25 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.30% | +1.18% | — | |
| 26 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.24% | — | — | |
| 27 | PFE | Pfizer Inc | Stock-Healthcare | 1.23% | -0.18% | +29.34% | |
| 28 | ONC | Beone Medicines Ltd-adr | Stock-Other | 1.23% | -0.15% | +163.61% | |
| 29 | KURA | Kura Oncology Inc | Stock-Other | 1.23% | +0.05% | — | |
| 30 | TRML | Tourmaline Bio Inc | Stock-Other | 1.23% | — | — | |
| 31 | ANAB | Anaptysbio Inc | Stock-Other | 1.23% | — | — | |
| 32 | TIL | Instil Bio Inc | Stock-Other | 1.19% | — | — | |
| 33 | ✓ | Immatics NV | Stock-Other | 1.18% | +1.02% | — | |
| 34 | BNTX | Biontech Se-adr | Stock-Other | 1.14% | +1.03% | -5.91% | |
| 35 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.10% | -0.20% | -22.30% | |
| 36 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.04% | -0.20% | +20.00% | |
| 37 | SYK | Stryker CORP | Stock-Healthcare | 1.02% | -0.03% | -36.07% | |
| 38 | INSM | Insmed Inc | Stock-Healthcare | 0.99% | -1.07% | -2.30% | |
| 39 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.96% | -1.12% | — | |
| 40 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.92% | +1.08% | -5.81% | |
| 41 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 0.86% | — | -0.80% | |
| 42 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 0.85% | -0.12% | — | |
| 43 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 0.77% | -0.21% | — | |
| 44 | DXCM | Dexcom Inc | Stock-Healthcare | 0.76% | +1.18% | -12.00% | |
| 45 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.76% | -0.39% | -34.35% | |
| 46 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.72% | -0.23% | -36.16% | |
| 47 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.70% | -0.43% | +52.45% | |
| 48 | VERA | Vera Therapeutics Inc | Stock-Other | 0.64% | -0.13% | +46.11% | |
| 49 | ✓ | Merus N V | Stock-Other | 0.54% | — | — | |
| 50 | GMED | Globus Medical Inc - A | Stock-Healthcare | 0.53% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ORIC | Oric Pharmaceuticals Inc | +1.5% | +1057.42% | Add |
| 2 | MBX | Mbx Biosciences Inc | +1.5% | NEW | New buy |
| 3 | PVLA | Palvella Therapeutics Inc | +1.4% | NEW | New buy |
| 4 | REPL | Replimune Group Inc | +1.4% | NEW | New buy |
| 5 | SLDB | Solid Biosciences Inc | +1.4% | NEW | New buy |
| 6 | RAPP | Rapport Therapeutics Inc | +1.4% | NEW | New buy |
| 7 | ZBIO | Zenas Biopharma Inc | +1.4% | NEW | New buy |
| 8 | VTYXUSD | Ventyx Biosciences Inc | +1.3% | NEW | New buy |
| 9 | TECX | Tectonic Therapeutic Inc | +1.3% | NEW | New buy |
| 10 | BCAX | Bicara Therapeutics Inc | +1.2% | NEW | New buy |
| 11 | KURA | Kura Oncology Inc | +1.2% | NEW | New buy |
| 12 | TRML | Tourmaline Bio Inc | +1.2% | NEW | New buy |
| 13 | ANAB | Anaptysbio Inc | +1.2% | NEW | New buy |
| 14 | RCUS | Arcus Biosciences Inc | +1.2% | +857.46% | Add |
| 15 | TIL | Instil Bio Inc | +1.2% | NEW | New buy |
| 16 | ✓ | Immatics NV | +1.2% | NEW | New buy |
| 17 | EW | Edwards Lifesciences CORP | +0.8% | NEW | New buy |
| 18 | ONC | Beone Medicines Ltd-adr | +0.6% | +163.61% | Add |
| 19 | ✓ | Merus N V | +0.5% | NEW | New buy |
| 20 | GMED | Globus Medical Inc - A | +0.5% | NEW | New buy |
| 21 | CNC | Centene CORP | +0.5% | NEW | New buy |
| 22 | OMDA | Omada Health Inc | +0.4% | NEW | New buy |
| 23 | CI | THE Cigna Group | +0.4% | NEW | New buy |
| 24 | SNDX | Syndax Pharmaceuticals Inc | +0.4% | NEW | New buy |
| 25 | KMTS | Kestra Medical Technologies, Ltd. | +0.4% | NEW | New buy |
| 26 | AVBP | Arrivent Biopharma Inc | +0.4% | +252.63% | Add |
| 27 | HNGE | Hinge Health Inc-a | +0.3% | NEW | New buy |
| 28 | VRTX | Vertex Pharmaceuticals Inc | +0.3% | +46.98% | Add |
| 29 | GPCR | Structure Therapeutics Inc | +0.3% | +52.45% | Add |
| 30 | SRRK | Scholar Rock Holding CORP | +0.2% | NEW | New buy |
| 31 | ASND | Ascendis Pharma A/S | +0.2% | +66.00% | Add |
| 32 | CAI | Caris Life Sciences Inc | +0.2% | NEW | New buy |
| 33 | VERA | Vera Therapeutics Inc | +0.1% | +46.11% | Add |
| 34 | INSM | Insmed Inc | +0.1% | -2.30% | Trim |
| 35 | TRVI | Trevi Therapeutics Inc | +0.1% | +64.00% | Add |
| 36 | TEM | Tempus Ai Inc-cl A | +0.1% | +74.07% | Add |
| 37 | ARGX | Argenx Se - Adr | +0.1% | +31.65% | Add |
| 38 | PFE | Pfizer Inc | +0.1% | +29.34% | Add |
| 39 | QURE | uniQure N.V. | 0% | -3.65% | Trim |
| 40 | BBIO | Bridgebio Pharma Inc | 0% | — | Unchanged |
| 41 | IOBTQ | Io Biotech Inc | 0% | +23.89% | Add |
| 42 | IONS | Ionis Pharmaceuticals Inc | 0% | -2.49% | Trim |
| 43 | MLTX | Moonlake Immunotherapeutics | 0% | — | Unchanged |
| 44 | CRSP | CRISPR Therapeutics AG | 0% | — | Unchanged |
| 45 | NBIX | Neurocrine Biosciences Inc | — | +1.89% | Add |
| 46 | RPRX | Royalty Pharma plc | — | — | Unchanged |
| 47 | ROIV | Roivant Sciences Ltd. | 0% | +2.25% | Add |
| 48 | VTRS | Viatris Inc | 0% | — | Unchanged |
| 49 | RXRX | Recursion Pharmaceuticals-a | 0% | — | Unchanged |
| 50 | INCY | Incyte CORP | 0% | -1.38% | Trim |
According to official SEC Form 13F filings, Sectoral Asset Management Inc reported a total U.S. public equity portfolio value of $143.3M across 94 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LENZ, LLY, UNH) accounted for 34.3% of total reported equity market value during Q2 2025.
Top New Position Initiated
MBX
市值: $2.2M
Top Position Liquidated / Trimmed
MDT
前期市值: $2.1M
During Q2 2025, Sectoral Asset Management Inc's top holdings by market value included LENZ (18.9%)、LLY (4.6%)、UNH (3.5%). The largest single position, LENZ, represented 18.9% of total portfolio value.
In Q2 2025, Sectoral Asset Management Inc made 88 total portfolio adjustments, initiating 25 new buys, adding to 23 positions, trimming 25 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.